VolitionRx (VNRX) announced submission for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species. At 97% specificity the assay detected 86% of feline lymphomas. Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5M contractual milestone payment. The Nu.Q Vet Canine test is already available in more than 20 countries.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX: